Stanley Black & Decker SWK
Industrials · Manufacturing - Tools & Accessories · Synthos Deep Dive · 2026-07-03
The Overview
Stanley Black & Decker makes the DeWalt, Craftsman, and BLACK+DECKER power tools you see at Home Depot and Lowe's, plus industrial fasteners for cars and airplanes. It's a 180-year-old company that got into trouble after the pandemic — it overstocked inventory, took on too much debt, and profits collapsed.
Right now it's a repair story: management is cutting costs, selling off pieces (it just sold an aerospace-parts unit for $1.6 billion to pay down debt), and trying to get profit margins back up. If that works, the earnings roughly double and the stock is reasonably priced. If it stalls — and sales are basically flat — you're holding a company with a lot of debt and a 3.6%-dividend as your consolation.
Our verdict is Watch: not cheap enough to buy on hope, not broken enough to avoid. Wait for proof the margins are actually recovering.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above average). It carries meaningful debt and its profits swing with the housing/DIY cycle, but a low-teens EV/EBITDA and a solid dividend give some cushion.
- Growth Quality 4/10 (below average). Sales are flat and margins are thin; this is a recovery, not a grower.
- Exponential Potential 2/10 (low). A mature toolmaker in a slow-growth market — no realistic path to multiplying several times over.
The one big worry: the debt. Net debt is nearly 5× yearly cash earnings. If the economy softens and tool demand drops, that leverage bites.
Putting a number on it: our fair-value estimate is $92 against a current price of $97.80 — a premium price for a business we still like.
Our summary metrics
Net-debt/EBITDA ~4.9× and 37× trailing EPS on a cyclical, but low-teens EV/EBITDA and a 3.6% dividend cushion.
Flat revenue, sub-10% EBITDA margin, ROIC ~6.6% — a margin-recovery story, not organic growth.
No acceleration, no TAM expansion — mature tools cyclical; the earnings recovery is a re-rate, not an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
No acceleration, no TAM expansion — mature tools cyclical; the earnings recovery is a re-rate, not an exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $88.67 (high $100 / low $82; 0 Strong Buy · 16 Buy · 19 Hold · 2 Sell → Hold) — context, not our anchor |
| Valuation | 37× trailing EPS · ~20× FY26E · ~17× FY27E · ~12× FY30E · EV/S 1.3× · EV/EBITDA 16.3× |
| Technicals | Uptrend — $91.90, −2.4% off 52-wk high, above 50/200-DMA, RSI 67, +30.5% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 expert voices, 0 KB claims. Fundamentals/quant only |
| Position sizing | Satellite / value-cyclical, ~1–2% if owned at all; not a core holding |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for SWK — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $97.80, 4% above the 50-day average ($94), 20% above the 200-day average ($81) — an uptrend. 6% below the 52-week high of $104, 57% above the 52-week low of $62.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $97.80 is currently inside the band (band $97–$105).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 50.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.78, negative momentum.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = SWK · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Stanley Black & Decker (NYSE: SWK), founded 1843 and headquartered in New Britain, CT, is a global maker of power tools, hand tools, outdoor equipment, and engineered fastening systems. Its brands include DeWalt, Craftsman, BLACK+DECKER, Stanley, and Cub Cadet. The company runs two reporting segments today: Tools & Outdoor (the vast majority of revenue) and Engineered Fastening (fasteners for automotive, aerospace, and industrial customers). Fiscal year ends late December / early January (FY2025 closed 2026-01-03).
Revenue mix (from filings):
- By geography (FY2025): United States $9.32B (~62%) · Europe $3.08B (~20%) · Asia $1.21B (~8%) · Canada $0.68B · Other North America $0.84B. US-centric, so it is directly exposed to US retail/DIY demand and to tariffs on imported goods (a headwind management called out in Q1'26).
- By segment (Q1'26 disclosure): Tools & Outdoor ~$3.34B (segment margin 8.3%) · Engineered Fastening ~$0.51B (segment margin 11.9%). FMP's product-segmentation history is coarse (it lumps most revenue into "Construction & Do-It-Yourself" in older years and shows only the Industrial/Fastening line separately), so the current two-segment split above comes from the earnings release.
The single most important corporate action in the file: on 2026-04-06 the company closed the sale of Consolidated Aerospace Manufacturing (CAM) to Howmet for $1.8B (~$1.6B net), using the proceeds to cut debt and fund buybacks. This sharpens the focus on the core tools business and is central to the deleveraging thesis (§9).
2. The expert thesis (traceable)
There is no expert thesis to report. The Synthos knowledge base contains 0 claims on SWK (total_claims: 0, net_bullish_voices: 0). No net-bullish voices, no cautionary voice, nothing to reconcile.
This is an honest and common outcome: SWK is a mature industrial cyclical that the high-conviction growth/tech voices in our panel simply do not cover. Accordingly, this entire note is fundamentals- and quant-driven, and the verdict carries Low conviction by construction. We do not manufacture conviction where the KB is silent. The Street's own read is telling: a Hold consensus (16 Buy / 19 Hold / 2 Sell) with a price target ($88.67) essentially at the current price — the professional community sees a fairly valued turnaround, not a mispriced opportunity.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Above-average | Net-debt/EBITDA ~4.9× TTM and 37× trailing EPS on a cyclical are the flags; offsetting them are a low-teens EV/EBITDA 16.3×, a 3.6% dividend, beta 1.20, and the CAM cash paying down debt. Historic max drawdown from peak ~−58% shows how much it can move. |
| Growth Quality | 4 · Below-average | Revenue is flat-to-down (FY23 $15.8B → FY25 $15.1B), EBITDA margin ~8% TTM, ROIC ~6.6%, ROE ~4%. This is a margin-recovery story (adj. EPS guided to $4.90–5.70) layered on a no-growth top line — quality is improving off a low base, not high. |
| Exponential Potential | 2 · Low | No revenue acceleration (Street models ~2% revenue CAGR to 2030), a mature ~$14B toolmaker in a slow-growth TAM with no adjacency ramp. The EPS "double" is a re-rate off a depressed base, not exponential growth. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Margin program lands: adj. EPS reaches ~$5.70 (top of guide) and Street believes the ~$7+ FY30 EPS path; deleveraging via CAM cash re-rates it toward a normalized ~16–17× fwd EPS on ~$6.50 mid-cycle EPS. | ~$118 (+28%) |
| Base (our anchor) | Guidance roughly hits mid-point (adj. EPS ~$5.30) but revenue stays flat and leverage only grinds down; the stock holds a ~15× fwd-EPS cyclical multiple on ~$6.10 EPS power. | ~$92 (~0%) |
| Bear | Retail/DIY softness deepens, tariffs bite, margin recovery stalls; EPS sticks near ~$4.50 and leverage keeps the multiple capped at ~11× on stressed EPS ~$6.00, plus a dividend-safety scare. | ~$66 (−28%) |
Synthos fair value = the base case, ~$92 (~flat), with the full $66–$118 span as the honest range. This anchor sits essentially on top of the Street's $88.67 consensus — an unusual case where our independent read and the Street agree the stock is close to fairly valued. That agreement is itself the argument for Watch rather than Buy: there is no obvious edge here today. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). SWK is neither today — it is a cyclical in recovery:
- Forward growth: revenue CAGR FY25→FY30E is only ~2.3% ($15.1B → ~$17.0B on Street estimates). EPS grows faster (FY26E ~$4.55 → FY30E ~$7.65, ~14% CAGR) but that is margin recovery off a depressed base, not unit/volume growth.
- Acceleration (2nd derivative): negative-to-flat on revenue. Organic revenue was down 1% in Q1'26 on North American retail softness; the top line has shrunk three years running. There is no demand inflection to ride.
- Room to run: at a ~$14B cap in a mature global tools market, there is no TAM-expansion story. Growth adjacencies (electrification of outdoor, pro-tool share gains) are incremental, not exponential.
- Reinvestment runway: capex is modest (~$283M, ~1.8% of revenue) and free cash flow (~$688M FY25) is largely committed to the dividend (~$501M) and debt. The CAM proceeds fund buybacks and deleveraging, not high-return organic reinvestment.
Exponential Potential: Low (2/10). Own SWK — if at all — for a cyclical earnings-recovery re-rate plus a 3.6% dividend, not for compounding or a multibagger. This is the honest opposite of a flagship next-exponential.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $15.13B, −1.5% (FY24 $15.37B, −2.6% on FY23 $15.78B). Down from the FY22 peak of $16.95B. The top line has been flat-to-declining for three years.
- Quarterly trajectory: Q1'25 $3.74B → Q2 $3.95B → Q3 $3.76B → Q4 $3.68B → Q1'26 $3.85B (+3% YoY reported, but flat organic — the gain was price + FX offset by −3% volume).
- Margins: gross ~30% TTM (recovered from the ~26% 2023 trough), but EBITDA margin only ~8% TTM and net margin ~2.4% TTM. Q1'26 adjusted EBITDA margin 9.2%. Margin recovery is real but still well below the company's historical mid-teens EBITDA.
- Earnings: net income $401.9M FY25 (EPS $2.65), a swing back to profit from FY23's −$281.7M loss. Q1'26 GAAP EPS $0.39 / adjusted EPS $0.80.
- Cash flow: operating CF ~$971M FY25, capex ~−$283M, FCF ~$688M. The dividend (~$501M) consumes the majority of FCF — payout on GAAP EPS is >100%, funded by the gap between GAAP earnings and cash flow (D&A add-back). Watch this.
- Balance sheet: total debt ~$6.0B, cash $0.28B, net debt ~$5.72B → net-debt/EBITDA ~4.9× TTM. This is the crux risk. The $1.6B CAM proceeds applied to debt in Q2'26 should meaningfully improve this — a key thing to verify at the next print. Goodwill + intangibles ($10.4B) exceed tangible book (tangible book/share is negative).
6. Valuation — priced in or room?
On trailing numbers SWK looks expensive (37× EPS) because earnings are still depressed. The bull case rests entirely on forward normalization: on live consensus the forward P/E is ~20× (FY26E ~$4.55) → ~17× (FY27E ~$5.39) → ~12× (FY30E ~$7.65). On EV/EBITDA the picture is more reasonable — 16.3× TTM, which compresses toward ~11–12× as EBITDA recovers to the ~$1.3–1.5B range analysts model. EV/Sales is cheap at 1.3×.
The honest read: SWK is fairly valued for a mid-cycle recovery, not cheap. You are paying ~15× normalized earnings for a flat-revenue, high-leverage cyclical — reasonable if the margin program delivers, unattractive if it stalls. Street targets (context): consensus $88.67, high $100, low $82 — the consensus sits below the current $91.90 price, i.e. the average analyst sees marginal downside. Our $92 base FV lands right at the current price. Not a value screen winner; a show-me valuation.
7. Technicals (computed from EOD price history)
- Trend: up. $91.90 sits above the 50-DMA ($80.91) and 200-DMA ($76.40), with the 50 above the 200 (golden-cross posture). MACD +3.78 (positive).
- Location: −2.4% off the 52-week high ($94.12) and +48% off the 52-week low ($62.12) — near the top of its range. But note the max drawdown from peak of ~−58% — this is a volatile name that fell hard in the 2022–23 crisis.
- Momentum: RSI(14) 67 — strong and approaching overbought (<70), so entry here is stretched; a pullback would be a lower-risk add.
- Relative strength: SWK +30.5% 12-mo vs SPY +20.6% and QQQ +30.3% — it has outperformed the market over the past year (the recovery trade working) and roughly matched the Nasdaq. +29% over 3 months, well ahead of SPY +13.7%.
- Read: technicals are constructive — the market is already pricing the recovery, which is why the risk/reward is only fair. Momentum near overbought argues for patience, not chasing.
8. Moat & competitive position
SWK's moat is brand and distribution scale, not technology: DeWalt and Craftsman are genuine category-leading pro/consumer brands with deep shelf presence at the big-box retailers, and that retail relationship + brand equity is a real barrier. But it is a mature, competitive, retail-dependent moat — exposed to Home Depot/Lowe's buying power (customer concentration), to Techtronic (Milwaukee/Ryobi) and Bosch as direct competitors, and to private-label and imported-tool pressure. Tools is cyclical (housing, DIY, pro construction), and the Engineered Fastening business ties earnings to auto and aerospace cycles.
Peer set (FMP-supplied industrials comps, market cap): Lincoln Electric $14.2B, Grupo Aeroportuario del Pacífico $13.2B, Applied Industrial $12.2B, Owens Corning $12.2B, Advanced Drainage Systems $11.7B, Donaldson $10.3B, Flowserve $9.2B, Toro $9.2B, Core & Main $8.4B, Pool Corp $8.0B. Note these are broad industrial comps, not pure tool peers (the closest true competitor, Techtronic, is Hong Kong–listed and not in the set). SWK is the largest by revenue but carries lower margins and higher leverage than most of this group — its multiple reflects that.
9. Management, capital allocation & guidance
- Capital allocation: the strategy is deleverage and simplify. The CAM divestiture ($1.6B net) went "the vast majority" to debt reduction in Q2'26, with remaining capacity earmarked for share repurchases (per CFO Patrick Hallinan). The dividend (~$3.32/share, 3.6% yield) is maintained but consumes most of FCF — a dividend that is covered by cash flow but not by GAAP EPS, so it depends on the margin recovery holding.
- Insider activity: recent Form-4s are routine — CEO Chris Nelson's RSU vesting / tax-withholding (M-Exempt and F-InKind at $91.67, 2026-06-29) and a director's equity award. No open-market discretionary buying or alarming selling in the sampled window. Neutral signal.
- Management's own guidance (half-weighted — their own book): From the 2026-04-29 8-K earnings release (SEC Item 2.02), management's self-interested forward guidance for FY2026: GAAP EPS $4.15–$5.35 (raised, reflecting the expected CAM sale gain) and adjusted EPS $4.90–$5.70 (reaffirmed, ~13% YoY growth at the midpoint). Free cash flow $500–700M including CAM tax/fees, or $700–900M excluding them. Management framed 1Q'26 as "on-track" with "sales, gross margin, and cash performance firmly on track with our full-year plan." This is management talking its own book and is half-weighted accordingly — but it is a real, dated earnings-release guide (not boilerplate), and it is the backbone of the recovery case. The adjusted-vs-GAAP gap ($0.35–0.75) is driven by footprint/restructuring charges partly offset by the CAM gain.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $1.21, revenue ~$3.96B). The Q2 print will also book the CAM sale gain and show the first post-deal balance sheet — watch the new net-debt/EBITDA figure.
- Margin trajectory: adjusted gross and EBITDA margins vs the plan — the whole thesis is margin recovery. Any slippage is a red flag.
- Organic revenue / North American retail: Q1'26 organic was −1% on retail softness. A return to positive organic volume would materially de-risk the story.
- Capital deployment: size and pace of the promised buybacks now that CAM cash is in hand.
- Tariffs & input costs: management flagged tariff expense offsetting pricing — a swing factor for margins.
Thesis tripwires (what would change the call): margin recovery stalling for two quarters; net-debt/EBITDA failing to improve after the CAM cash; a dividend-coverage scare; or renewed organic-revenue declines beyond −low-single-digits.
11. Key risks
- Leverage (structural): net-debt/EBITDA ~4.9× on a cyclical is the dominant risk. If EBITDA disappoints, the balance sheet, dividend, and multiple all come under pressure at once.
- Cyclicality / demand: tools revenue tracks housing, DIY, and pro-construction cycles; Fastening tracks auto/aero. A macro slowdown hits both.
- Flat top line: three years of flat-to-down revenue — the EPS story is entirely margin/cost driven, which is finite. Without volume growth, the re-rate has a ceiling.
- Customer concentration: heavy reliance on Home Depot/Lowe's gives retailers pricing leverage.
- Tariffs & FX: US-centric revenue with imported product exposes margins to tariff and currency swings (a stated Q1'26 headwind).
- Dividend coverage: the 3.6% yield is covered by cash flow but not GAAP EPS; a cash-flow miss puts it in question.
- Zero expert coverage: no independent Synthos-panel conviction supports (or challenges) the fundamentals here — a breadth gap, not a strength.
12. Verdict, position sizing & monitoring
Watch. SWK is a competently-run, well-branded tools cyclical mid-turnaround: margins are recovering off a 2023 trough, the CAM sale strengthens the balance sheet, and management's $4.90–5.70 adjusted-EPS guide would make the stock cheap on normalized earnings. But revenue is flat, leverage is high (~4.9× net-debt/EBITDA), the recovery is not yet proven, and there is zero expert conviction in the KB — and both our own fair value (~$92) and the Street's ($88.67) land right at today's price. There is no discernible edge to buying here today; the risk/reward is symmetric.
- Sizing: if owned at all, a satellite value/income position, ~1–2% — not a core holding. The 3.6% dividend is the paid-to-wait; the margin recovery is the upside call.
- Monitoring: re-underwrite on the §10 tripwires; the 2026-07-29 print (margins + post-CAM leverage) is the key near-term tell. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $91.90.
- Single biggest risk: the balance sheet — nearly 5× net-debt/EBITDA on a cyclical means the turnaround has to deliver.
What would move it to Buy: two clean quarters of margin recovery plus net-debt/EBITDA falling below ~3.5× plus a return to positive organic revenue — at a lower entry price (toward the $80 rising 50-DMA).
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — SWK has no expert coverage in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven, and the conviction rating is Low by construction. Fabricated conviction is structurally impossible (claim-ID reconciliation) and none is asserted here.
- Data as-of: fundamentals 2026-04-04 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the 2026-04-29 8-K. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: SWK management guidance (FY26 adj. EPS $4.90–5.70) is management's own book, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").